Costs of breast cancer recurrence after initial treatment for HR+, HER2−, high-risk early breast cancer: estimates from SEER-Medicare linked data-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Costs of breast cancer recurrence after initial treatment for HR+, HER2−, high-risk early breast cancer: estimates from SEER-Medicare linked data

Published:2023-12-19 Issue:1 Volume:27 Page:84-96
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Vitko Alexandra S.¹,Martin Pam²,Zhang Sheng²,Johnston Adam²,Ohsfeldt Robert²³,Zheng Shen⁴,Liepa Astra M.¹

Affiliation:

1. Value, Evidence, and Outcomes (VEO) – Oncology, Eli Lilly and Company, Indianapolis, IN, USA

2. Medical Decision Modeling Inc, Indianapolis, IN, USA

3. Texas A&M University, College Station, TX, USA

4. TechData Service Company, King of Prussia, PA, USA

Funder

Eli Lilly and Company

California Department of Public Health

Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries

National Cancer Institute’s Surveillance, Epidemiology and End Results Program

University of California, San Francisco

University of Southern California

Public Health Institute

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2291266

Reference33 articles.

1. Breast Cancer Statistics, 2022

2. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

3. Breast Cancer Treatment

4. Differences in Breast Cancer Survival by Molecular Subtypes in the United States

5. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. U.S. payer budget impact of using an AI-augmented cancer risk discrimination digital histopathology platform to identify high-risk of recurrence in women with early-stage invasive breast cancer;Journal of Medical Economics;2024-07-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3